Home » Posts tagged 'doxylamine succinate'
Tag Archives: doxylamine succinate
Doxylamine succinate

Doxylamine succinate
CAS NO. 562-10-7,
Sperber et al. Journal of the American Chemical Society, 1949 , vol. 71, p. 887,889
see
Application of Toluene in the Synthesis of Doxylamine Succinate KC. Chaluvaraju1*, MD. Karvekar2 and AR. Ramesha3 1Department of Pharmaceutical Chemistry, Govt. College of Pharmacy, Bengaluru, Karnataka, India. 2Department of Pharmaceutical Chemistry, Krupanidhi College of Pharmacy, Bengaluru, Karnataka, India. 3R&D, R L Fine Chemicals, Bengaluru, Karnataka, India.
ABSTRACT In the present study an efficient method for the synthesis of Doxylamine succinate in the presence of toluene is described. The yield and purity of the product prepared by this method has been found to be better in comparison to reported method. The structure of the synthesized compound was characterised by its melting point and spectral data’s (IR, I HNMR, 13CNMR and Mass spectra). The data obtained are in good agreement with the literature found for Doxylamine succinate.
m.p-102-103°C.
1HNMR (CDC13) δ ppm: 8.5 (d, J = 2.4 Hz ,1H; Het-H) ,7.6-7.0 (m,8H; Ar-H+ Het-H), 3.5-3.3 (t, J = 6.6 Hz, 2H;-OCH2), 2.6-2.5 (t, J = 3.0 Hz, 2H; – CH2), 2.3-2.2 (s, 6H, -N(CH3)2).2.0-1.9 (s, 3H, -CH3).
I3CNMR (CDC13) δ ppm: 148.17, 145.55, 136.17, 127.84, 126.62, 126.21, 121.50, 120.77, 81.81, 61.11, 59.39, 45.91, 23.76.
MS (EI) m/z: 271 (M+ ), 257, 226, 182.
nmr…………http://file.selleckchem.com/downloads/nmr/S424001-Doxylamine-succinate-HNMR-Selleck.pdf

nmr predict of succinate


nmr predict of free base
CAS NO. 469-21-6, N,N-dimethyl-2-(1-phenyl-1-pyridin-2-ylethoxy)ethanamine H-NMR spectral analysis


http://www.google.com/patents/CN102108059B?cl=en
Doxylamine succinate following structural formula:
CAS Number: 562-10-7
Formula = C21H28N2O5
Molecular weight: 388.46
III SUMMARY OF THE INVENTION
The present invention aims to provide a class of antihistamines ethanol as doxylamine succinate, the technical problem to be solved is the selection of a new simple synthetic methods.
The synthesis of doxylamine succinate process route is:
The synthesis of 2-acetyl-pyridine as starting materials, including synthetic and doxylamine salt-forming reaction and the separation and purification process of each unit, wherein the first synthetic doxylamine by The reaction of 2-acetyl pyridine Grignard reagent with bromobenzene and magnesium to produce 2-pyridyl generated methylcarbinol, then 2-pyridyl-methyl-phenyl methanol with sodium amide and sequentially generates 2-dimethylamino ethyl chloride reaction Doxylamine, most 后多西拉敏 a salt with succinic acid to give the title product doxylamine succinate.
the synthesis of doxylamine
150ml three-necked flask of xylene 40ml, weighed 2. 34g (0. 06mol) was added sodium amide three-neck flask, weighed 10g (0.05mol) 2- pyridyl methylcarbinol dissolved in 20ml of xylene was slowly added dropwise, followed by stirring.After the addition was complete, the oil bath was heated 150 ° C, maintained under reflux of xylene, the reaction was refluxed for 5 hours. Color from pale yellow reaction solution gradually turned dark brown, solid gradually dissolved.
The dried mixture of 2-dimethylamino ethyl chloride was added 20ml of xylene dropping funnel was slowly added dropwise to the three-necked flask. After the addition was complete, maintaining at reflux for 20 hours. TLC monitoring of the reaction process, the reactants and products change (V petroleum ether: V ethyl acetate = 5: 1).
After stopping the reaction, the oil bath was removed, and the reaction solution was cooled to room temperature, with ice-bath, was slowly added dropwise to the reaction solution 50ml of ice water, stirred for half an hour. The reaction solution was separated, the organic phase was retained and the aqueous phase was extracted with xylene (3 * 40ml), the combined organic
Phase. Drying, filtration, rotary evaporation to remove xylene.
The obtained crude product was subjected to silica gel mixed with the sample, the liquid sample with the silica mass ratio of 1: 2, dissolved in ethyl acetate, and stirred for half an hour, the solvent was removed by rotary evaporation. The mixed sample was subjected to column chromatography on silica gel, eluting with a mixed solvent (V petroleum ether: V ethyl acetate = 2: 1) petroleum ether and ethyl acetate eluent until the 2-pyridyl-methyl-phenyl The complete collection of components of methanol to stop the elution. The eluent was collected and the solvent was removed by rotary evaporation, after recycling the recovered 2-pyridyl-methyl-phenyl methanol and dried in vacuo.
The chromatography column of silica gel and the eluent was poured into the remaining single-necked flask, and the crude product was added mass of diethylamine, stirred for half an hour, filtration, and the solvent was removed by rotary evaporation and the liquid diethyl amine, to give doxylamine 7. 3g, 54% yield. Gas content was 99%. (Column chamber temperature 250 ° C, detection temperature 300 ° C, vaporization temperature of 300 ° C).
1HNMr (CDCI3), δ: 8 · 51 (1Η, m), 7 · 60-7 61 (2Η, m), 7 · 40 (2Η, m), 7 · 27 (2Η, m),. 7. 18 (1Η, m), 7. 09 (1H, m), 3. 41 (2H, m), 2. 59 (2H, m), 2. 27 (6H, s), 1. 98 (3H , s).
3, doxylamine succinate synthesis of
Doxylamine 1. 35g (0. 005mol) and succinic 0. 59g (0. 005mol) was added IOml single-necked flask, adding acetone 7ml, heating and stirring until dissolved, stirring was continued for half an hour, the heating was stopped. Cooled to room temperature and then placed in the refrigerator freezer -20 ° C for 24 hours. Filtration, the solid was placed in a vacuum desiccator the residual solvent was distilled off, and dried for 6 hours. The crude product was dissolved by heating continued recrystallized from acetone (Ig doxylamine succinate: 2.5mL acetone). Steps above, doxylamine succinate, and recrystallized to give 1.6g, 82% yield. Mp 101-103 ° C.
] 1HNMr (CDCI3), δ: 8 · 54 (1Η, m), 7 · 69 (1Η, m), 7 · 51 (1Η, m), 7 · 32 (2Η, m), 7 · 30 ( 2Η, m), 7. 23 (1Η, m), 7. 16 (1H, m), 3. 63 (2H, m), 3. 18 (2H, m), 2. 80 (6H, s), 2. 54 (4H, s), 1. 99 (3H,S) O
| CN1447694A | Jun 21, 2001 | Oct 8, 2003 | 达切斯内公司 | Rapid onset formulation |
| Reference | ||
|---|---|---|
| 1 | Bachman, G. Bryant等.Heterogeneous bimolecular reduction. II. Direct acylation of pyridine and its homologs and analogs.《Journal of Organic Chemistry》.1957,第22卷1302-1308. | |
| 2 | CHARLESH . TILFORD等.Histamine Antagonists. Basically Substituted Pyridine Derivatives.《Journal of the American Chemical Society 》.1948,第70卷4001-4009. | |
……………….
FDA Approves Diclegis for Pregnant Women Experiencing Nausea and Vomiting
doxylamine
pyridoxine
8 april 2013
The U.S. Food and Drug Administration today approved Diclegis (doxylamine succinate and pyridoxine hydrochloride) to treat pregnant women experiencing nausea and vomiting. Diclegis is a delayed-release tablet intended for women who have not adequately responded to conservative management of nausea and vomiting during pregnancy, such as dietary and lifestyle modifications.
These modifications include eating several small meals instead of three large meals, eating bland foods that are low in fat and easy to digest and avoiding smells that can trigger nausea. “Many women experience nausea and vomiting during pregnancy, and sometimes these symptoms are not adequately managed through recommended changes in diet and lifestyle,” said Hylton V. Joffe, M.D., M.M.Sc., director of the Division of Reproductive and Urologic Products in the FDA’s Center for Drug Evaluation and Research.
“Diclegis is now the only FDA-approved treatment for nausea and vomiting due to pregnancy, providing a therapeutic option for pregnant women seeking relief from these symptoms.” Diclegis was studied in 261 women experiencing nausea and vomiting due to pregnancy. Study participants in the clinical trial were at least 18 years old and had been pregnant for at least 7 weeks and up to 14 weeks. Women were randomly assigned to receive two weeks of treatment with Diclegis or a placebo.
The study results showed that women taking Diclegis experienced greater improvement in nausea and vomiting than those taking placebo. Additionally, observational (epidemiological) studies have shown that the combination of active ingredients in Diclegis does not pose an increased risk of harm to the fetus. Diclegis is taken daily. Tablets must be taken whole on an empty stomach. The recommended starting dose is two tablets taken at bedtime.
If symptoms are not adequately controlled, the dose can be increased to a maximum recommended dose of four tablets daily (one in the morning, one mid-afternoon and two at bedtime). Nausea and vomiting due to pregnancy usually improve after the first trimester. Health care professionals should reassess their patients for continued need for Diclegis as pregnancy progresses. Drowsiness or sleepiness, which can be severe, is the most common side effect reported by women taking Diclegis.
Women should avoid using Diclegis when engaging in activities requiring mental alertness, such as driving or operating heavy machinery, until cleared to do so by their health care provider.
Diclegis is marketed by Duchesnay Inc., based in Blainville, Québec, Canada.
DRUG APPROVALS BY DR ANTHONY MELVIN CRASTO
.....

















